Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tailored support for seniors may speed recovery after CAR-T cancer treatment

NCT ID NCT06052826

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times

Summary

This study tests whether a geriatric assessment—checking physical function, thinking skills, and nutrition—followed by tailored support (physical therapy, delirium prevention, and nutritional help) can help people aged 60 and older recover faster after CAR-T therapy for B-cell non-Hodgkin lymphoma or multiple myeloma. About 164 participants will be split into two groups: one gets the extra support, the other gets standard care. The main goal is to see if the extra support improves physical function 30 days after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

geriatric assessment and tailored interventions (physical therapy, cognitive education, nutritional support)

What this could lead to

If it works, this could show that personalized geriatric care helps older adults recover faster and with fewer side effects after CAR-T therapy.

What could go wrong

This is a mid-stage trial with 164 participants, so results may not apply to everyone. The interventions are supportive, not a direct treatment for the cancer itself.

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.